TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26701344

Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC) intervention
Number of subjects: 177

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 177
Study: 25908323

Group type: EXPERIMENTAL
Intervention: Benfotiamine (BF) 600mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Benfotiamine (BF)
Number of subjects: 85
Study: 24074927

Group type: EXPERIMENTAL
Intervention: WP‐CRT
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: WP‐IMRT
Number of subjects: 44
Study: 21917759

Group type: EXPERIMENTAL
Intervention: PVAG (prednisone, vinblastine, doxorubicin, gemcitabine)
Number of subjects: 59
Study: 18162657

Group type: EXPERIMENTAL
Intervention: Positive stereotypical beliefs toward Asian Americans in a realistic threat context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endorsement of both positive and negative stereotypes of Asian Americans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental situations involving interactions with Asian Americans in realistic threat contexts
Number of subjects: 0
Study: 17018669

Group type: EXPERIMENTAL
Intervention: Home safety program (n = 100 participants)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Social visits (n = 96)
Number of subjects: 391
Study: 14679105

Group type: EXPERIMENTAL
Intervention: Q fever complement-fixing antigen (QFA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunostimulants (general category including QFA)
Number of subjects: 0
Study: 11094866

Group type: EXPERIMENTAL
Intervention: Nicotrol NS (3 mg nicotine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8818489

Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride 0.1%
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 0.075%
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study: 1317765

Group type: EXPERIMENTAL
Intervention: L-tryptophan (2 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (normotensive group)
Number of subjects: 15
Study: 3830478

Group type: EXPERIMENTAL
Intervention: Auditory attention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Visual distraction
Number of subjects: 22
Study: 30509375

Group type: EXPERIMENTAL
Intervention: Emergency physician ultrasound for the identification of gastric contents
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Expert review of ultrasound images
Number of subjects: 45
Study: 30566730

Group type: EXPERIMENTAL
Intervention: PSE (900mg/day for 17 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PSE
Number of subjects: 10

Group type: COMPARATOR
Intervention: PL (placebo, equivalent amount for 17 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PL
Number of subjects: 10
Study: 27417562

Group type: EXPERIMENTAL
Intervention: Caloric restriction diet (goal: 10% weight loss), N = 118
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (225 minutes/week of moderate-to-vigorous activity), N = 117
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combined diet + exercise, N = 117
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control, N = 87
Number of subjects: 439
Study: 24925079

Group type: EXPERIMENTAL
Intervention: Rubber Hand Illusion (RHI) in BDD group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Rubber Hand Illusion (RHI) in healthy control group
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Rubber Hand Illusion (RHI)
Number of subjects: 17
Study: 21954995

Group type: EXPERIMENTAL
Intervention: Treadmill training with body weight support (TTBWS) plus traditional training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional training alone
Number of subjects: 60
Study: 20099987

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg/day
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/day
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ziprasidone 320 mg/day
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg/day
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Haloperidol 15 mg/day
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Haloperidol 30 mg/day
Number of subjects: 59
Study: 19026036

Group type: EXPERIMENTAL
Intervention: Midostaurin 25 mg twice daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Midostaurin 50 mg twice daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Midostaurin 75 mg twice daily
Number of subjects: 37
Study: 16189072

Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) 800 mg/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 12925463

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh; an endothelium‐dependent vasodilator) administered via transdermal iontophoresis in infants born at term (n=19)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh; an endothelium‐dependent vasodilator) administered via transdermal iontophoresis in infants born preterm (n=35)
Number of subjects: 54
Study: 11716647

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) and waist-hip ratio (WHR) as predictors of serum triglycerides
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Endurance run test (physical fitness) as a predictor of serum HDL-C
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Sum of adipose polyunsaturated fatty acids as a measure of long-term dietary fat intake
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Obesity and fat centrality
Number of subjects: 831
Study: 9189190

Group type: EXPERIMENTAL
Intervention: Multidisciplinary case management with individualized care plans
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard emergency care (control)
Number of subjects: 70
Study: 8263271

Group type: EXPERIMENTAL
Intervention: Prenatal vitamins (TRN, Natalins Rx, Filibon Forte, Prenatal Formula, Materna, Stuartnatal)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (1 g table salt)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sucrose capsule (1 g sucrose)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Vitamin C (2000 mg)
Number of subjects: 9
Study: 3577722

Group type: EXPERIMENTAL
Intervention: Early weight bearing
Number of subjects: 46

Group type: COMPARATOR
Intervention: Late weight bearing
Number of subjects: 46
Study: 28466569

Group type: EXPERIMENTAL
Intervention: Amylase added to SC+ porridges
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Amylase added to SC porridges
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Amylase added to porridges
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Amylase-added porridges
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control SC+ porridges
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control SC porridges
Number of subjects: 120
Study: 27237345

Group type: EXPERIMENTAL
Intervention: Integrating evidence‐based practice into research
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional research (Control)
Number of subjects: 120
Study: 24731521

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (2 g over 20 minutes)
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Nebulised magnesium sulphate (3 × 500 mg over 1 hour)
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Placebo (standard therapy alone)
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate vs Placebo
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Nebulised magnesium sulphate vs Placebo
Number of subjects: 1109
Study: 23111204

Group type: EXPERIMENTAL
Intervention: Rességuier Method (RM) followed by Qi Gong (QG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Qi Gong (QG) followed by Rességuier Method (RM)
Number of subjects: 30
Study: 21152828

Group type: EXPERIMENTAL
Intervention: 40 mg Trifolium pratense, 1 capsule/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo capsules containing lactose, 1 capsule/day
Number of subjects: 120
Study: 18257183

Group type: EXPERIMENTAL
Intervention: Abdominal cluster‐needling
Number of subjects: 87

Group type: COMPARATOR
Intervention: Western medicine (Prostat Tablets)
Number of subjects: 87
Study: 15927388

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention (15 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No intervention (15 weeks)
Number of subjects: 53
Study: 12637480

Group type: EXPERIMENTAL
Intervention: Intravenous irinotecan (40 to 125 mg/m2 every 2 weeks) plus oral ciclosporin (5 mg/kg bid for 3 days)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intravenous irinotecan plus oral ciclosporin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intravenous irinotecan
Number of subjects: 37
Study: 12237188

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 10533946

Group type: EXPERIMENTAL
Intervention: Education intervention on antibiotic use
Number of subjects: 157

Group type: COMPARATOR
Intervention: Unrelated topic intervention (Control)
Number of subjects: 157
Study: 8636523

Group type: EXPERIMENTAL
Intervention: Siemens Servo 900 C (SC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ohmeda CPU 1 (CPU)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Engström Erica (EE)
Number of subjects: 9
Study: 2258877

Group type: EXPERIMENTAL
Intervention: Dietary counselling
Number of subjects: 28
Study: 7368972

Group type: EXPERIMENTAL
Intervention: Cardioselective beta-blockade
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cardioselective beta-blockade, Diazepam, Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Early treatment after onset of symptoms
Number of subjects: 87
Study: 6098034

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g im) plus daily placebo injections with probenicid (1 g orally)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g im on each of three days) plus probenicid (1 g orally)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single-dose cefotaxime (1 g im) plus probenicid (1 g orally)
Number of subjects: 20
Study: 31222794

Group type: EXPERIMENTAL
Intervention: Endocut
Number of subjects: 60

Group type: COMPARATOR
Intervention: Autocut
Number of subjects: 60
Study: 29052083

Group type: EXPERIMENTAL
Intervention: Patient-specific devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 27118495

Group type: EXPERIMENTAL
Intervention: Postoperative drainage autologous blood re-transfusion (ABT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional postoperative vacuum drainage (Drain)
Number of subjects: 91
Study: 24405258

Group type: EXPERIMENTAL
Intervention: Counterforce brace 1
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Counterforce brace 2
Number of subjects: 34

Group type: COMPARATOR
Intervention: No brace (control)
Number of subjects: 34
Study: 23160441

Group type: EXPERIMENTAL
Intervention: Daily lens replacement each morning
Number of subjects: 215

Group type: COMPARATOR
Intervention: Monthly lens replacement (historical control)
Number of subjects: 215
Study: 20816284

Group type: EXPERIMENTAL
Intervention: Microimplant placement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tooth extraction
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Transgingival microimplant placement
Number of subjects: 28
Study: 18245030

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Continuation medication
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Withdrawal from medication
Number of subjects: 180
Study: 15736775

Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone coverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: No coverage
Number of subjects: 0
Study: 12762134

Group type: EXPERIMENTAL
Intervention: Talsaclidine (n = 34)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Talsaclidine (n = 31)
Number of subjects: 40
Study: 10835801

Group type: EXPERIMENTAL
Intervention: Coach
Number of subjects: 22

Group type: COMPARATOR
Intervention: Triflo-II
Number of subjects: 22
Study: 8640420

Group type: EXPERIMENTAL
Intervention: Asymmetric film‐screen system
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional film‐screen system
Number of subjects: 49
Study: 1451927

Group type: EXPERIMENTAL
Intervention: Sultamicillin (50 mg/kg in two equal doses each day for a mean of 10 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefaclor (40 mg/kg in three equal doses each day for a mean of 11 days)
Number of subjects: 30
Study: 4057139

Group type: EXPERIMENTAL
Intervention: Group A: local anaesthetic medially and laterally to the neurovascular bundle only
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group B: local anaesthetic medially, laterally, and dorsally
Number of subjects: 61

Group type: COMPARATOR
Intervention: Group A
Number of subjects: 61
Study: 30808022

Group type: EXPERIMENTAL
Intervention: GDNF (120 μg per putamen)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 29980424

Group type: EXPERIMENTAL
Intervention: Tyrosine supplementation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 27093771

Group type: EXPERIMENTAL
Intervention: Sodium perborate solution for 5 minutes per day combined with brushing
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate solution for 5 minutes per day combined with brushing
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group brushed with coconut soap and a soft toothbrush
Number of subjects: 45
Study: 25410068

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia (7.5 mg hypobaric bupivacaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bilateral spinal anesthesia (12 mg hypobaric bupivacaine)
Number of subjects: 60
Study: 21741471

Group type: EXPERIMENTAL
Intervention: Standard care plus a 45-min psychological intervention (relaxation and guided imagery) with take-home relaxation CDs for 3 days before and 7 days after surgery.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 60
Study: 20484002

Group type: EXPERIMENTAL
Intervention: TeachTown: Basics (CAI program)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 18319308

Group type: EXPERIMENTAL
Intervention: Estrogen-progestin treatment (EPT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15944847

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg o.d.)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (1,000/125 mg t.i.d.) plus roxithromycin (150 mg b.i.d.)
Number of subjects: 349
Study: 12866746

Group type: EXPERIMENTAL
Intervention: Diane 35 plus CPA (cyproterone acetate [2 mg] and ethinyl estradiol [35 microg])
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diane 35 plus spironolactone [100 mg]
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Spironolactone [100 mg] alone
Number of subjects: 79
Study: 11299606

Group type: EXPERIMENTAL
Intervention: Database coverage for health sciences librarianship journals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Search strategies for library literature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grey literature of librarianship
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systems designed for tracking research evidence
Number of subjects: 0
Study: 8803395

Group type: EXPERIMENTAL
Intervention: Gallium alloy restorations
Number of subjects: 60
Study: 1511371

Group type: EXPERIMENTAL
Intervention: Screening for colorectal cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current screening guidelines of the American Cancer Society and the National Cancer Institute
Number of subjects: 0
Study: 6821615

Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30319467

Group type: EXPERIMENTAL
Intervention: 25, 40, or 55 h placement budgets (job coaches' time resources)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Obtaining a job
Number of subjects: 116
Study: 27060174

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 1050
Study: 26090941

Group type: EXPERIMENTAL
Intervention: 0.3% Hydroxypropyl Methylcellulose/Dextran (HPMC/dextran)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.18% Sodium Hyaluronate (SH)
Number of subjects: 70
Study: 23168373

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (8 g CHO per kg body mass)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low carbohydrate diet (3 g CHO per kg body mass)
Number of subjects: 22
Study: 20880596

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mg kg(‐1) in saline (20 mL)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Saline (20 mL)
Number of subjects: 110
Study: 18854793

Group type: EXPERIMENTAL
Intervention: Lidocaine + Ketorolac (30 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lidocaine + Ketorolac (30 mg) + Dexamethasone (8 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lidocaine (3 mg x kg‐1)
Number of subjects: 45
Study: 16878206

Group type: COMPARATOR
Intervention: 50% silver nitrate (NIT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.2% rhodamine B (ROD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% methylene blue (MET)
Number of subjects: 30
Study: 12499333

Group type: EXPERIMENTAL
Intervention: High-fat meal (760 kcal)
Number of subjects: 25

Group type: COMPARATOR
Intervention: High-carbohydrate meal (isoenergetic)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-fat meal with dietary antioxidants (865 kcal)
Number of subjects: 25
Study: 10818325

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 247

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Sevoflurane (patients over 50 years)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Isoflurane (patients over 50 years)
Number of subjects: 247
Study: 8888436

Group type: EXPERIMENTAL
Intervention: SF 68 strain (150 x 10^6 CFU, three times a day for 5 days)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: SF 68 strain
Number of subjects: 211
Study: 1814322

Group type: EXPERIMENTAL
Intervention: Oestradiol (4, 2, or 1 mg) + Norethisterone acetate (1 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (2 mg) + Cyproterone acetate (1 mg) + Calcium (1000 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Oestradiol valerate + Cyproterone acetate without Calcium
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 6359851

Group type: EXPERIMENTAL
Intervention: Nadolol (80 to 240 mg)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (5 to 10 mg)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Combination of Bendroflumethiazide and Nadolol (B + N)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Hydralazine (25 to 100 mg twice daily)
Number of subjects: 365
Study: 30896990

Group type: EXPERIMENTAL
Intervention: Home visiting program (Healthy Families Massachusetts)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Control group (referred to other services)
Number of subjects: 704
Study: 28992526

Group type: EXPERIMENTAL
Intervention: Pharmacogenetics-guided treatment
Number of subjects: 685

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 685
Study: 26559142

Group type: EXPERIMENTAL
Intervention: Laser‐1st treatment (Selective laser trabeculoplasty)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Medicine‐1st treatment (IOP-lowering drops)
Number of subjects: 718
Study: 23316850

Group type: EXPERIMENTAL
Intervention: High efficacy physical activity messages with high health risk information
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Low efficacy physical activity messages with high health risk information
Number of subjects: 611

Group type: COMPARATOR
Intervention: Low efficacy physical activity messages with no health risk information
Number of subjects: 611

Group type: COMPARATOR
Intervention: High efficacy physical activity messages with no health risk information
Number of subjects: 611
Study: 21083685

Group type: EXPERIMENTAL
Intervention: Secure attachment promotion programme (experimental group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Educational talk (control group)
Number of subjects: 72
Study: 19122308

Group type: EXPERIMENTAL
Intervention: Nocturnal home oxygen therapy (HOT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (non-HOT)
Number of subjects: 20
Study: 17031643

Group type: EXPERIMENTAL
Intervention: Doc-Gem (gemcitabine 900 mg/m² on days 1 and 8, docetaxel 75 mg/m² on day 1, every 3 weeks for up to six cycles)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cis-Gem->Doc (gemcitabine 900 mg/m² on days 1 and 8, cisplatin 70 mg/m² on day 1 for three cycles, followed by docetaxel 100 mg/m² on day 1 for three cycles)
Number of subjects: 113
Study: 15061244

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 262

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 262
Study: 11235929

Group type: EXPERIMENTAL
Intervention: Risperidone (mean daily dose = 3.8 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pimozide (mean daily dose = 2.9 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pimozide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 50
Study: 9551840

Group type: EXPERIMENTAL
Intervention: Complex partial seizures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondarily generalized seizures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 7577282

Group type: EXPERIMENTAL
Intervention: Abdominal wall lift
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional pneumoperitoneum
Number of subjects: 25